Roland Houben

BRAFV600Emutations in malignant melanoma are associated with increased expressions of BAALC (2008)

Schrama, David, Keller, Gunhild, Houben, Roland, Ziegler, Christian G, Vetter-Kauczok, Claudia S, Ugurel, Selma, ...

Abstract Bachground Activating BRAF mutations are present in approximately 50% of melanomas. Although different downstream target genes of the most common mutant V600E have been identified, the...

RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO (2007)

Houben, Roland, Ortmann, Sonja, Becker, Juergen C

Abstract Background The Raf kinase inhibitor protein (RKIP) has been shown to block MAP kinase pathway as well as NFκB signalling. By means of immunohistochemistry, we previously demonstrated that...

The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report (2006)

Becker, Jürgen C, Houben, Roland, Vetter, Claudia S, Bröcker, Eva B

Abstract Background Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30...

Absence of mutations in the coding sequence of the potential tumor suppressor 3pK in metastatic melanoma (2005)

Houben, Roland, Becker, Jürgen C, Rapp, Ulf R

Abstract Background Activation of Ras or Raf contributes to tumorigenesis of melanoma. However, constitutive Raf activation is also a characteristic of the majority of benign melanocytic nevi and...

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis (2004)

Houben, Roland, Becker, Jürgen C, Kappel, Andreas, Terheyden, Patrick, Bröcker, Eva-B, Goetz, Rudolf, ...

Abstract Background Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are...